Michael H. Davidson to Antineoplastic Agents
This is a "connection" page, showing publications Michael H. Davidson has written about Antineoplastic Agents.
Connection Strength
0.124
-
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004 Apr 15; 116(8):546-54.
Score: 0.108
-
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
Score: 0.015